TMS for Symptom Reduction in Schizophrenia
| Status: | Recruiting |
|---|---|
| Conditions: | Schizophrenia |
| Therapuetic Areas: | Psychiatry / Psychology |
| Healthy: | No |
| Age Range: | 21 - 62 |
| Updated: | 9/23/2018 |
| Start Date: | October 2016 |
| End Date: | July 2021 |
| Contact: | Xiaoming Du, PhD |
| Email: | xdu@mprc.umaryland.edu |
| Phone: | 410-402-6036 |
Neuroimaging studies suggest that aberrant activities at specific brain regions such as
sensory areas and language-related areas are related to psychosis symptoms including auditory
and visual hallucination, delusion, and thought disorders. Transcranial magnetic stimulation
(TMS) provides a non-invasive means for altering brain electrical neural activity. TMS has
been approved by FDA for treatment of depression. Other applications have not been approved
but it has been used in a wide range of clinical research especially in neurology and
psychiatry. Among psychotic symptoms, there are preliminary significant improvement in
treatments of auditory hallucination using TMS with small samples, but those treatments are
not robust in larger samples. The high inter-subject variability limits the efficacy of TMS
treatment in schizophrenia patients. We aim to develop a TMS treatment method with a
fMRI-defined treatment target area, where the TMS target is individually identified to
maximize the TMS effects. The identification method uses both the anatomical character and
its functional relationship with auditory hallucination and other psychosis symptoms. If the
current target-identification successfully identified effective TMS target individually, the
treatment efficacy will be significant improved and more patients will benefit from TMS
treatment.
sensory areas and language-related areas are related to psychosis symptoms including auditory
and visual hallucination, delusion, and thought disorders. Transcranial magnetic stimulation
(TMS) provides a non-invasive means for altering brain electrical neural activity. TMS has
been approved by FDA for treatment of depression. Other applications have not been approved
but it has been used in a wide range of clinical research especially in neurology and
psychiatry. Among psychotic symptoms, there are preliminary significant improvement in
treatments of auditory hallucination using TMS with small samples, but those treatments are
not robust in larger samples. The high inter-subject variability limits the efficacy of TMS
treatment in schizophrenia patients. We aim to develop a TMS treatment method with a
fMRI-defined treatment target area, where the TMS target is individually identified to
maximize the TMS effects. The identification method uses both the anatomical character and
its functional relationship with auditory hallucination and other psychosis symptoms. If the
current target-identification successfully identified effective TMS target individually, the
treatment efficacy will be significant improved and more patients will benefit from TMS
treatment.
Inclusion Criteria:
- Male and Female between ages 21-62
- Ability to give written informed consent (age 21 or above)
- For patient participants, Evaluation to Sign Consent (ESC) 10 or greater.
- Medication stability for 4 weeks (same drugs at same dosages)
Exclusion Criteria:
- Any history of seizures
- Any Family history of epilepsy in first degree relatives
- Significant alcohol or other drug use (substance dependence within 6 months or
substance abuse within 1 month) other than nicotine or marijuana dependence.
- Any major medical illnesses that may affect normal brain functioning. Examples of
these conditions include, but not limited to, stroke, CNS infection or tumor, other
significant brain neurological conditions.
- Taking > 400 mg clozapine/day
- Failed TMS screening questionnaire
- Cardiac pacemakers, implanted medication pumps, intracardiac lines, or acute, unstable
cardiac disease, with intracranial implants (e.g. aneurysm clips, shunts, stimulators,
cochlear implants, or electrodes) or any other metal object within or near the head,
excluding the mouth,that cannot be safely removed.
- History of head injury with loss of consciousness over 10 minutes; history of brain
surgery
- Can not refrain from using alcohol and/or marijuana 24 hours or more & cigarette
smoking half and hour or more prior to experiments.
- Woman who is pregnant (child-bearing potential but not on contraceptive and missing
menstrual period; or by self report; or by positive pregnancy test)
We found this trial at
1
site
621 West Lombard Street
Baltimore, Maryland 21201
Baltimore, Maryland 21201
(410) 706-7101
Phone: 410-402-6036
University of Maryland, Baltimore Welcome to the University of Maryland, Baltimore (UMB) founded in 1807...
Click here to add this to my saved trials
